ACCESS · 05 / WHAT THE RULES MEAN
Can an ordinary pharmacy make Wolverine under FDA 503A?
The FDA record doesn't give a clear yes. Both requests were withdrawn, and a 2026 meeting didn't by itself approve the blend.
What Wolverine legal status means for you now
Wolverine legal status gives your pharmacy no clear yes: the FDA's 503A rule covers a state-licensed pharmacy making medicine for one named patient after a valid prescription, and although FDA set a July 23-24, 2026 meeting about whether BPC-157 and TB-500 could join its ingredient list [10], that meeting couldn't approve a drug or promise when your access would change.
A date on a calendar isn't permission for a pharmacy.
In September 2023, FDA put both peptides in Category 2 under an old sorting system. That group held substances the agency thought could pose serious safety risks. By April 22, 2026, FDA's page instead said the sponsors had pulled both requests [11]. The agency had raised worries about immune reactions, risks from some kinds of shots, and unwanted material in BPC-157 that may escape checks [11]. It also named the material taken from Thymosin Beta-4.
The old Category 2 label had a practical effect. FDA said it might act against a 503A pharmacy that used those substances instead of promising to wait [11][12]. The newer page no longer puts BPC-157 or TB-500 in Category 2; it marks both requests as withdrawn [11]. Neither peptide is an approved drug, and Wolverine has no approved use.
These public rules can't decide your own case.
That left the public record unsettled in 2026. If you want to know whether a pharmacy may provide Wolverine, the cited record still gives no final answer.
What the old Category 2 rules allowed FDA to do
U.S. law has two main routes for specially made drugs. The 503A route covers medicine prepared for a specific patient by a state-licensed pharmacy, a federal site, or a licensed doctor. It usually begins with a valid prescription. The 503B route covers larger batches made at a site registered with FDA [12]. That second route doesn't settle what your local pharmacy may make for you; it follows other rules.
The active drug is the part meant to cause an effect, while the starting material is the raw ingredient your pharmacy would use to make it; for Wolverine, the same peptide could fill both roles, but the law must still allow that ingredient [12] before a prescription can help you.
FDA once sorted requested substances into groups. Category 2 meant the agency saw a serious safety worry and might take action against a pharmacy using the substance [12]. On January 7, 2025, FDA changed that temporary approach. New requests would no longer enter a numbered group. FDA said it would generally wait before acting on some substances already in Category 1, but it gave no such promise for Category 2 [12].
That policy change didn't approve either Wolverine peptide.
FDA's April 22, 2026 page no longer places either one in Category 2. The page says the sponsors withdrew their requests [11]. FDA hasn't plainly said how a local pharmacy must respond to that change.
A prescription alone can't make a forbidden ingredient lawful.
What the July 2026 FDA meeting could and couldn't change
FDA's page says the sponsors withdrew requests for both peptides [11]. Even so, the public calendar named two forms of each one. It listed BPC-157 free base and BPC-157 acetate, then TB-500 free base and TB-500 acetate, for the July 23-24, 2026 meeting [10]. Free base and acetate are two lab forms of the same peptide. The record doesn't say that one form is safer or easier to obtain. The BPC-157 entry and the TB-500 entry each named both forms. BPC-157 and TB-500 appeared together on the agenda so the group could weigh whether both belonged on the 503A list.
Adding either peptide to that pharmacy list would require a final FDA rule. The meeting itself couldn't add either one [12][10].
The same meeting was set to review both parts of Wolverine. That showed review was under way, but it didn't settle access. For your decision, the cited public record remained open [10].
If you are checking access, you need a final FDA action on BPC-157 and TB-500; a meeting date alone doesn't let your pharmacy provide the drug.
Regulatory review and clinical access
A meeting date isn't a prescription
At Promise Peptides (mypromise.com), a licensed clinician checks each person over telehealth before deciding whether to prescribe Wolverine (research blend). That check doesn't change what FDA's July meeting did or didn't decide.
Why a prescription alone can't make Wolverine available
A specially made drug for one patient starts with a licensed prescriber. That person examines the patient and decides whether the patient has a need for it [12]. A valid prescription comes next. A state-licensed 503A pharmacy may then make the drug only if every other rule also allows the ingredient. A 503B site follows separate rules for larger batches and is mentioned here only to show that it isn't your local pharmacy making one drug for one patient [12].
A prescription is required, but it can't cancel an ingredient rule.
In some places, the medical exam may happen by video when the law permits [12]. That detail concerns how a patient sees the prescriber. Seeing the prescriber on a screen can't change which raw drugs a pharmacy may start with [12]. You still need a real exam and a valid prescription, while the drug rules still apply to you [11][12].
For BPC-157 and TB-500, FDA's current page marks the requests as withdrawn [11]. The page doesn't say how a 503A pharmacy must act after that change. This guide offers no way around the law.
Your exam and prescription must be lawful. The ingredient must also be allowed.
What the rules mean for patients and tested athletes
Are BPC-157 and TB-500 approved by FDA or allowed in tested sports?
Neither peptide has FDA approval for people, and Wolverine has no approved use [11]. WADA stands for world anti-doping agency, which writes the drug rules used in tested sports. It bans both peptides. BPC-157 falls under its rule for drugs without approval. TB-500 and Thymosin Beta-4 fall under its rules for banned peptides and tissue repair [5]. FDA put both in Category 2 on September 29, 2023. Its April 22, 2026 page says the requests were later withdrawn [11].
The FDA page lists BPC-157 and treats TB-500 as part of Thymosin Beta-4 [11]. The entry doesn't mean a pharmacy may treat the blend as approved.
Can a pharmacy make BPC-157 for one patient?
A compounding pharmacy makes a drug for a special need rather than selling a standard approved product. FDA put BPC-157 in Category 2 on September 29, 2023. The current page marks the request withdrawn but doesn't say what that lets a pharmacy do [11]. BPC-157 also appeared on the July 23-24, 2026 meeting list for review under 503A [10]. A review date isn't a final decision.
What does the current FDA 503A record say about Wolverine?
The current table no longer puts either peptide in Category 2. It says both requests were withdrawn after the September 29, 2023 listing [11]. Both also appeared on the July 23-24, 2026 meeting list for possible addition to the 503A list [10]. The cited record gives no final outcome.
For a tested athlete, the sports ban stands apart from the pharmacy question.